

DNA MICROARRAYS:
EXPERIMENTOS COMPARATIVOS

JUAN CARLOS OLIVEROS COLLAZOS

BioinfoGP, CNB-CSIC

GENOMAS, GENES Y PROTEÍNAS

GENOMA:

CONJUNTO DE TODOS LOS GENES DE UN ORGANISMO

GEN:


UNIDAD DE ALMACENAMIENTO DE INFORMACIÓN GENÉTICA

CUALQUIER ELEMENTO DEL CROMOSOMA MEDIANTE EL CUAL SE TRANSMITEN LOS CARACTERES DE UN ORGANISMO


SECUENCIA DE ADN (O ARN), ESENCIAL PARA UNA DETERMINADA FUNCIÓN FISIOLÓGICA

PROTEÍNA:


SECUENCIAS DE AMINOÁCIDOS QUE ACTUAN COMO ENZIMAS, ELEMENTOS ESTRUCTURALES, HORMONAS, ETC.



nobelprize.org





GENOMAS, GENES Y PROTEÍNAS




DEL GENOMA
•ESTÁTICO, ÚNICO

AL PROTEOMA
•DINÁMICO, MÚLTIPLE



REGULACIÓN DE LA ACTIVIDAD GÉNICA



VARIOS NIVELES:

- TRANSCRIPCIÓN

- MADURACIÓN

- TRANSPORTE AL CITOPLASMA

- DEGRADACIÓN

- TRADUCCIÓN

- POST-TRADUCCIÓN

REGULACIÓN DE LA ACTIVIDAD GÉNICA

LOS GENES NO ACTÚAN DE FORMA AISLADA

EXISTEN REDES DE INTERACCIÓN


- FÍSICA (DIRECTA O INDIRECTA)
- FUNCIONAL

CIERTA CO-REGULACIÓN ES NECESARIA

**LOS *DNA MICROARRAYS* PERMITEN
MONITORIZAR LA EXPRESIÓN DE MILES
DE GENES A LA VEZ, EN CIENTOS DE
CONDICIONES FISIOLÓGICAS**

BASES DE LA TECNOLOGÍA DE *DNA MICROARRAYS*


HIBRIDACIONES TIPO *NORTHERN* PARA LA MEDICIÓN DEL NIVEL DE TRANSCRIPCIÓN DE UN GEN EN DISTINTOS TEJIDOS



- FASE SÓLIDA: EXTRACTO CELULAR (RNA)
- FASE LÍQUIDA: SONDA MARCADA

BASES DE LA TECNOLOGÍA DE *DNA MICROARRAYS*

UN *DNA MICROARRAY* CONSISTE EN UNA COLECCIÓN DE SONDAS GÉNICAS ORDENADAS EN UN SOPORTE SÓLIDO




•FASE SÓLIDA: SONDA

•FASE LÍQUIDA: EXTRACTO CELULAR (cDNA MARCADO)


BASES DE LA TECNOLOGÍA DE *DNA MICROARRAYS*

CADA SONDA ESTÁ **DISEÑADA PARA UNIRSE A UN GEN** DE FORMA ESPECÍFICA




Duggan y col. (1999)

BIOLOGÍA, ESTADÍSTICA E INFORMÁTICA




BIOLOGÍA, ESTADÍSTICA E INFORMÁTICA

EXPERIMENTO BÁSICO



1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------




↑
Cuantificación

Digitalización

Imagen compuesta


**ESTA NUEVA FORMA DE EXPERIMENTAR
REQUIERE EL DESARROLLO DE NUEVAS
HERRAMIENTAS DE ANÁLISIS Y DE
VISUALIZACIÓN DE RESULTADOS**

ANÁLISIS DE IMÁGENES



www.moleculardevices.com

ANÁLISIS DE IMÁGENES




www.moleculardevices.com




ANÁLISIS DE IMÁGENES

**DE LA ESCALA DE
GRISES AL COLOR**

MUTANTE






SILVESTRE



COMPOSICIÓN

ANÁLISIS DE IMÁGENES

COLORES Y VALORES DE INTENSIDADES


	SILVESTRE (G)	MUTANTE (R)
 =	7298	7523
 =	3231	12034
 =	11245	3663

PROCESAMIENTO DE DATOS INICIALES

REPRESENTACIONES GRÁFICAS

R versus G

$\log_2 R$ versus $\log_2 G$



M versus A

$$C = \frac{R}{G}$$

$$M = \log_2 C$$

$$A = \frac{\log_2 R + \log_2 G}{2}$$



PROCESAMIENTO DE DATOS INICIALES

NORMALIZACIÓN DE VALORES

- CADA VALOR DE INTENSIDAD PROVIENE DE UNA IMAGEN (CANAL) INDEPENDIENTE
- ES NECESARIO HACER QUE ESTOS VALORES SEAN COMPARABLES
- AJUSTE BÁSICO: IGUALAR LA INTENSIDAD MEDIA DE AMBAS IMÁGENES



PROCESAMIENTO DE DATOS INICIALES

AJUSTE POR REGRESIÓN LINEAL



PROCESAMIENTO DE DATOS INICIALES

AJUSTE POR LOWESS



ESTADÍSTICA CON POCAS MUESTRAS

**DE TODOS LOS GENES PRESENTE EN EL
MICROARRAY:**

¿CUALES SE INDUCEN?


¿CUALES SE REPRIMEN?

UMBRALES *MÁGICOS*:


- TASA DE CAMBIO >2 (INDUCIDOS)
- TASA DE CAMBIO < -2 (REPRIMIDOS)

ESTADÍSTICA CON POCAS MUESTRAS

TASA DE CAMBIO +/- 2



VALOR Z +/- 2



MÉTODO PROPUESTO POR
JOHN QUACKENBUSH

ESTADÍSTICA CON POCAS MUESTRAS

EN CUALQUIER EXPERIMENTO BIOLÓGICO ES ESENCIAL CONOCER EL GRADO DE REPRODUCIBILIDAD DE LAS MEDIDAS

REPETIR EXPERIMENTOS DE *MICROARRAYS* ES COSTOSO

LA CANTIDAD DE MUESTRA BIOLÓGICA PUEDE SER EL FACTOR LIMITANTE

ESTADÍSTICA CON POCAS MUESTRAS

RÉPLICAS TÉCNICAS vs RÉPLICAS BIOLÓGICAS:

LAS RÉPLICAS TÉCNICAS SUPONEN UN MENOR COSTE

**LA VARIABILIDAD DE LAS RÉPLICAS TÉCNICAS ES
MUCHO MENOR**

**LAS RÉPLICAS TÉCNICAS NO DAN INFORMACIÓN ÚTIL
SOBRE LA REPRODUCIBILIDAD DE LOS VALORES DE
EXPRESIÓN GÉNICA**

ESTADÍSTICA CON POCAS MUESTRAS


T-TEST

W. S. GOSSETT
(REINO UNIDO, 1876-1937)




ESTADÍSTICA CON POCAS MUESTRAS

DATOS PROCEDENTES DE UN EXPERIMENTO SIN RÉPLICAS




ESTADÍSTICA CON POCAS MUESTRAS

DATOS PROCEDENTES DE UN EXPERIMENTO CON VARIAS RÉPLICAS



ESTADÍSTICA CON POCAS MUESTRAS

ANÁLISIS ESTADÍSTICO: VALORES P




VALOR P < 0.01

1019 GENES!

ESTADÍSTICA CON POCAS MUESTRAS

ANÁLISIS ESTADÍSTICO: TASA DE FALSOS POSITIVOS (FDR)




bioalma

VALOR P (AJUSTADO) < 0.01

27 GENES

ESTADÍSTICA CON POCAS MUESTRAS

ANÁLISIS ESTADÍSTICO: TASA DE FALSOS POSITIVOS (FDR)



bioalma

VALOR P (AJUSTADO) <math>< 0.05</math>

282 GENES

APLICACIÓN:

(MODIFICACIÓN DE LA EXPRESIÓN GÉNICA ASOCIADA AL EJERCICIO FÍSICO)

©2005 FASEB

The FASEB Journal express article 10.1096/fj.04-3149fje. Published online June 28, 2005.

Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise



D. J. Mahoney,* G. Parise,[†] S. Melov,[§] A. Safdar,[‡] and M. A. Tarnopolsky[‡]

Department of *Medical Sciences, [†]Kinesiology, [‡]Pediatrics and Medicine, McMaster University, Hamilton, Ontario, Canada; and [§]Buck Institute for Age Research, Novato, California 94945

Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise

D. J. Mahoney,* G. Parise,[†] S. Melov,[‡] A. Safdar,[‡] and M. A. Tarnopolsky[‡]

Department of *Medical Sciences, [†]Kinesiology, [‡]Pediatrics and Medicine, McMaster University, Hamilton, Ontario, Canada; and [§]Buck Institute for Age Research, Novato, California 94945



Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise

D. J. Mahoney,* G. Parise,[†] S. Melov,[‡] A. Safdar,[†] and M. A. Tarnopolsky[‡]Department of *Medical Sciences, [†]Kinesiology, [‡]Pediatrics and Medicine, McMaster University, Hamilton, Ontario, Canada; and [§]Buck Institute for Age Research, Novato, California 94945


Differentially increased gene expression after exercise

Gene Name	Accession Number	3 H	48 H	Potential Relevant Function
Metabolism and mitochondria				
Forkhead transcription factor O1A	AA134749	5.2±2.6	1.1±0.4	• activates PDK4 and PGC1 α
*Pyruvate dehydrogenase kinase 4	AA169469	3.5±1.2	1.3±0.5	• negatively regulates pyruvate dehydrogenase
Mitochondrial ribosomal protein L2	N94366	3.4±1.4	5.5±2.8	• involved in mitochondrial translation
IL-6 receptor	T52330	3.1±0.5	2.3±0.7	• subunit for IL-6 receptor complex
Ras-related associated with Diabetes	W84445	2.9±0.8	2.6±2.1	• a role in glucose metabolism
*PPAR γ coactivator 1 α	N89673	2.9±0.8	0.6±0.1	• regulates mitochondrial biogenesis
*PPAR γ	AA088517	2.7±0.7	1.4±0.6	• positively regulates fat metabolism
Nuclear receptor binding protein 2	N30573	2.6±0.4	3.8±0.9	• binds to and co-modulates PPAR α
Aminolevulinic acid δ synthetase 2	AA699919	2.3±0.4	1.5±0.1	• catalyzes first step in the heme biosynthesis
Interferon regulatory factor 1	AA478043	2.1±0.3	1.0±0.1	• transcription factor for iNOS expression
IL-6 signal transducer (gp130)	T61343	2.0±0.1	1.5±0.1	• component for IL-6 receptor complex
†PPAR δ	n/a	2.6±0.6	1.1±0.1	• positively regulates fat metabolism
†PPAR α	n/a	1.7±0.1	1.6±0.4	• positively regulates fat metabolism
Oxidant stress and signaling				
Metallothionein 1G	H53340	7.5±0.6	2.4±0.9	• metallothioneins are involved in protection against oxidative stress, metal ion homeostasis and detoxification, cell proliferation and apoptosis; transiently responds to most forms of stress or injury providing cytoprotective action, particularly oxidative injury.
Metallothionein 1H	H77766	7.0±1.0	2.0±0.5	
Metallothionein 1F	N55459	6.6±1.8	2.3±1.0	
Metallothionein 3	AI362950	6.1±0.9	1.6±0.8	
Metallothionein 1B	H72722	5.3±0.8	2.0±0.6	
Metallothionein 2A	AA872383	4.7±0.5	2.2±1.0	
Metallothionein 1L	AI289110	4.2±0.4	2.2±0.5	
Tyrosyl-DNA phosphodiesterase 1	AI215965	6.7±4.1	8.0±4.0	• repairs free-radical DNA double-strand breaks
*JunB	N94468	4.9±0.4	n/a	• part of AP-1 complex
Interferon regulatory factor 1	AA478043	2.1±0.3	1.0±0.1	• O ₂ ⁻ mediated transcription factor
Electrolyte transport				
NMDA receptor	R88267	n/a	25±16	• role in synaptic plasticity
*Ca ²⁺ ATPase (SERCA 3)	AA857542	4.5±0.8	1.6±0.6	• pumps Ca ²⁺ into SR
Solute carrier 17 (1)	N73241	3.9±1.4	2.7±0.3	• Sodium phosphate carrier
Na ⁺ /K ⁺ ATPase (β 3)	AA489275	2.7±0.2	n/a	• regulatory component of Na ⁺ /K ⁺ ATPase
Chloride channel 4	AA019316	2.4±0.3	0.6±0.2	• regulates cell volume, intracellular pH
Solute carrier 22 (3)	AA460012	2.4±0.5	1.9±0.5	• Mediates transport of organic cations
GABA receptor	R40790	2.2±0.3	2.3±0.3	• chloride channel; inhibitory neurotransmitter

Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise

D. J. Mahoney,* G. Parise,[†] S. Melov,[‡] A. Safdar,[‡] and M. A. Tarnopolsky[‡]

Department of *Medical Sciences, [†]Kinesiology, [‡]Pediatrics and Medicine, McMaster University, Hamilton, Ontario, Canada; and [§]Buck Institute for Age Research, Novato, California 94945



APLICACIÓN:

(MODIFICACIÓN DE LA EXPRESIÓN GÉNICA ASOCIADA AL EJERCICIO FÍSICO)

©2005 FASEB

The FASEB Journal express article 10.1096/fj.04-3149fje. Published online June 28, 2005.

Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise

D. J. Mahoney,^{*} G. Parise,[†] S. Melov,[§] A. Safdar,[‡] and M. A. Tarnopolsky[‡]

Department of ^{*}Medical Sciences, [†]Kinesiology, [‡]Pediatrics and Medicine, McMaster University, Hamilton, Ontario, Canada; and [§]Buck Institute for Age Research, Novato, California 94945

APLICACIÓN: (MODIFICACIÓN GENÉTICA EN MAMÍFEROS)

MOLECULAR AND CELLULAR BIOLOGY, May 2006, p. 3610–3624
0270-7306/06/\$08.00+0 doi:10.1128/MCB.26.9.3610–3624.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Vol. 26, No. 9

Disruption of Spermatogenic Cell Adhesion and Male Infertility in Mice Lacking TSLC1/IGSF4, an Immunoglobulin Superfamily Cell Adhesion Molecule†

Daisuke Yamada,¹ Midori Yoshida,² Yuko N. Williams,¹ Takeshi Fukami,¹ Shinji Kikuchi,¹ Mari Masuda,¹ Tomoko Maruyama,¹ Tsutomu Ohta,³ Dai Nakae,² Akihiko Maekawa,² Tadaichi Kitamura,⁴ and Yoshinori Murakami^{1*}

Tumor Suppression and Functional Genomics Project¹ and Genetics Division,³ National Cancer Center Research Institute, Tokyo, Japan; Department of Pathology, Sasaki Institute, Sasaki Foundation, Tokyo, Japan²; and Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan⁴

Disruption of Spermatogenic Cell Adhesion and Male Infertility in Mice Lacking TSLC1/IGSF4, an Immunoglobulin Superfamily Cell Adhesion Molecule†

Daisuke Yamada,¹ Midori Yoshida,² Yuko N. Williams,¹ Takeshi Fukami,¹ Shinji Kikuchi,¹ Mari Masuda,¹ Tomoko Maruyama,¹ Tsutomu Ohta,³ Dai Nakae,² Akihiko Maekawa,² Tadaichi Kitamura,⁴ and Yoshinori Murakami^{1*}




FIG. 6. Detection of apoptosis by TUNEL assays. (A and B) Histochemistry of the testes from *Tslc1*^{+/+} (A) and *Tslc1*^{-/-} (B) mice by TUNEL assay. Cells stained brown are TUNEL-positive cells. Nuclei were counterstained with methyl green (green). Closed arrowheads and open arrowheads indicate spermatocytes and spermatids, respectively. The open arrow indicates the sloughed cell. (C) Ratios of TUNEL-positive tubules to total tubules. (D) Average numbers of TUNEL-positive cells in TUNEL-positive tubules.




FIG. 8. Weights of testes and numbers of normal sperm during postnatal development of *Tslc1*^{+/+} and *Tslc1*^{-/-} mice. (A) Weights of testes. (B) Numbers of normal sperm. *, $P < 0.05$; **, $P < 0.005$; ***, $P < 0.0001$.


Disruption of Spermatogenic Cell Adhesion and Male Infertility in Mice Lacking TSLC1/IGSF4, an Immunoglobulin Superfamily Cell Adhesion Molecule†

Daisuke Yamada,¹ Midori Yoshida,² Yuko N. Williams,¹ Takeshi Fukami,¹ Shinji Kikuchi,¹ Mari Masuda,¹ Tomoko Maruyama,¹ Tsutomu Ohta,³ Dai Nakae,² Akihiko Maekawa,² Tadaichi Kitamura,⁴ and Yoshinori Murakami^{1*}

AFFYMETRIX MURINE ARRAY (U74Av2)

18400 SONDAS

**2 EXPERIMENTOS INDEPENDIENTES
(RÉPLICAS BIOLÓGICAS)**



Disruption of Spermatogenic Cell Adhesion and Male Infertility in Mice Lacking TSLC1/IGSF4, an Immunoglobulin Superfamily Cell Adhesion Molecule†

Daisuke Yamada,¹ Midori Yoshida,² Yuko N. Williams,¹ Takeshi Fukami,¹ Shinji Kikuchi,¹ Mari Masuda,¹ Tomoko Maruyama,¹ Tsutomu Ohta,³ Dai Nakae,² Akihiko Maekawa,² Tadaichi Kitamura,⁴ and Yoshinori Murakami^{1*}

TABLE 3. Genes up- and down-regulated in testes from *Tslc1*^{-/-} mice

Gene product	Accession no.	Microarray analysis results			Quantitative RT-PCR analysis results ^b		P value ^c
		Signal intensity ^a		Ratio of <i>Tslc1</i> ^{-/-} value/ <i>Tslc1</i> ^{+/+} value	<i>Tslc1</i> ^{-/-} value	<i>Tslc1</i> ^{+/+} value	
		<i>Tslc1</i> ^{-/-}	<i>Tslc1</i> ^{+/+}				
Up-regulated genes in <i>Tslc1</i> ^{-/-} testes							
Phospholipase A2, group XIA (Pla2g12a)	AI845798	13,102	771	17.0	11 ± 2.1	4.1 ± 0.8	0.03
Purine-nucleoside phosphorylase (Pnp)	U35374	1,629	410	4.0	6.1 ± 0.7	2.5 ± 0.6	0.02
<i>Mus musculus</i> cDNA 5' end clone	AA874329	706	272	2.6			
FUS interacting protein 1 (Fusip1)	AF060490	695	282	2.5			
Hemoglobin, beta adult major chain (Hbb-b1)	J00413	1,446	636	2.3			
DnaJ homolog, subfamily A, member 2 (Dnaja2)	AA763945	1,833	860	2.1	470 ± 160	300 ± 120	NS
Vascular cell adhesion molecule 1 (Vcam1)	U12884	2,321	1,546	1.5	110 ± 5.8	38 ± 2.5	0.0002
Guanylate kinase 1 (Guk1)	U53514	3,225	2,294	1.4	23 ± 12	4.4 ± 0.1	NS
Angiopoietin-like 4 (Angpt14)	AF110520	6,143	4,823	1.3	3.1 ± 0.2	1.2 ± 0.2	0.002
Down-regulated genes in <i>Tslc1</i> ^{-/-} testes							
Immunoglobulin superfamily 4 (Igsf4/Tslc1)	AF061260	444	3,943	0.11	0 ± 0	100 ± 18	0.001
Immunoglobulin superfamily 4 (Igsf4/Tslc1)	AB021966	690	3,739	0.18			
Platelet/endothelial cell adhesion molecule 1 (Pecam1)	L06039	181	799	0.23	1.6 ± 0.2	1.2 ± 0.3	NS
<i>Mus musculus</i> cDNA 3' end clone	AW047207	241	895	0.27			
Peroxiredoxin 2 (Prdx2)	U20611	281	892	0.31	16 ± 3.0	11 ± 0.6	NS
Dehydrogenase/reductase X chromosome (Dhrsx)	AI846822	4,509	11,760	0.38	11 ± 1.6	12 ± 2.1	NS
Ornithine decarboxylase antizyme 3 (Oaz3)	AB016275	17,735	44,962	0.39	94 ± 6.8	150 ± 9.2	0.007
Splicing factor, arginine/serine-rich 16 (Sfrs16)	AF042799	430	1,030	0.42			
Protein phosphatase 2, regulatory subunit B, beta isoform (Ppp2r2b)	AW048155	6,134	14,358	0.43	9.2 ± 1.9	23 ± 1.5	0.004
Mouse endogenous murine leukemia virus modified polytopic provirus DNA	M17327	789	1,769	0.45			
Deleted in polyposis 1-like 1 (Dp11l)	AA755260	14,224	29,836	0.48	340 ± 30	970 ± 130	0.008
Lysophospholipase 1 (Lypla1)	U89352	6,971	14,600	0.48	7.8 ± 0.4	5.6 ± 1.6	NS
Suppressor of K ⁺ transport defect 3 (Skd3)	U09874	7,709	15,612	0.49			
S100 calcium binding protein A13 (S100a13)	X99921	773	1,430	0.54			
Protamine 1 (Prm1)	Z47352	18,600	31,700	0.58	12,000 ± 2,200	16,000 ± 1,700	NS
RAN GTPase activating protein 1 (Rangap1)	U20857	4,960	8,480	0.58	72 ± 33	110 ± 47	NS
Growth arrest-specific protein 6 (Gas6)	X59846	1,120	1,820	0.61	80 ± 8.2	170 ± 35	0.04
Bcl2-associated athanogene 1 (Bag1)	AF022223	3,412	5,546	0.61	0.1 ± 0.1	1.1 ± 0.4	NS
Cyclin-dependent kinase inhibitor 1C (Cdkn1c)	U22399	1,090	1,650	0.66	2.3 ± 0.2	1.8 ± 0.1	NS
Mothers against decapentaplegic homolog 6 (Smad6)	AF010133	2,070	2,930	0.70	79 ± 11	94 ± 8.4	NS
Sperm mitochondrion-associated cysteine-rich protein (Smcp)	M88463	29,700	38,900	0.76	430 ± 43	930 ± 81	0.002

^a Average value of two independent experiments.

^b The Amount of Igsf4/Tslc1 in the *Tslc1*^{+/+} testis was assigned a value of 100. Data are average values ± SE of three to five independent experiments.

^c NS, not significant.

APLICACIÓN: (MODIFICACIÓN GENÉTICA EN MAMÍFEROS)

MOLECULAR AND CELLULAR BIOLOGY, May 2006, p. 3610–3624
0270-7306/06/\$08.00+0 doi:10.1128/MCB.26.9.3610–3624.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Vol. 26, No. 9

Disruption of Spermatogenic Cell Adhesion and Male Infertility in Mice Lacking TSLC1/IGSF4, an Immunoglobulin Superfamily Cell Adhesion Molecule†

Daisuke Yamada,¹ Midori Yoshida,² Yuko N. Williams,¹ Takeshi Fukami,¹ Shinji Kikuchi,¹ Mari Masuda,¹ Tomoko Maruyama,¹ Tsutomu Ohta,³ Dai Nakae,² Akihiko Maekawa,² Tadaichi Kitamura,⁴ and Yoshinori Murakami^{1*}

Tumor Suppression and Functional Genomics Project¹ and Genetics Division,³ National Cancer Center Research Institute, Tokyo, Japan; Department of Pathology, Sasaki Institute, Sasaki Foundation, Tokyo, Japan²; and Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan⁴